Amended Statement of Beneficial Ownership (3/a)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

MARGOLIN YAEL

2. Date of Event Requiring Statement (MM/DD/YYYY) 1/1/2023

3. Issuer Name and Ticker or Trading Symbol

BiondVax Pharmaceuticals Ltd. [BVXV]

(Last) (First) (Middle)

JERUSALEM BIOPARK, 2ND FLOOR, HADASSAH EIN KEREM CAMPUS

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Street)

JERUSALEM, L3 9112001

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)
1/3/2023

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares ⁽²⁾	66800	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Options (right to buy)	⁽¹⁾	11/19/2029	Ordinary Shares ⁽²⁾	720000	$0.182	D
Stock Options (right to buy)	⁽³⁾	4/6/2031	Ordinary Shares ⁽²⁾	1000000	$0.174	D
Restricted Share Units	⁽⁴⁾	4/6/2031	Ordinary Shares ⁽²⁾	133200	⁽⁵⁾	D

Explanation of Responses:
(1)	Stock options were granted on March 24, 2020 and are fully vested.
(2)	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents four hundred Ordinary Shares.
(3)	Stock options were granted on April 6, 2021 and vest on a monthly basis during a period of three years.
(4)	Restricted share units were granted on April 6, 2021 and vest on a monthly basis during a period of three years.
(5)	Each restricted share unit represents a contingent right to receive one ordinary share.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
MARGOLIN YAEL JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM, L3 9112001	X

Signatures
/s/ Yael Margolin		1/23/2023
^**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Grafico Azioni BiondVax Pharmaceuticals (NASDAQ:BVXV)
Storico
Da Apr 2024 a Mag 2024

Grafico Azioni BiondVax Pharmaceuticals (NASDAQ:BVXV)
Storico
Da Mag 2023 a Mag 2024

BVXV BiondVax Pharmaceuticals Ltd